Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

1.6 Balance sheet and capital expenditure

1.11 Capital expenditure

1.11 Capital expenditure

In 2020, the tangible capital expenditure resulting from UCB biopharmaceutical activities amounted to € 256 million (2019: €  99 million) and are mainly related to the new campus site in the UK and the Bioplant in Belgium.

Acquisition of intangible assets reached € 93 million in 2020 (2019: € 195 million) and is related to in-licensing deals, capitalized eligible development costs and software.

In addition, as foreseen in the agreement between UCB and Lonza for the manufacturing by Lonza of PEGylated antibody fragment-based bulk active compounds, UCB has participated in the pre-financing of the related capital expenditure. Depreciation charges on this investment are recognized in the cost of goods sold and are added back for recurring EBITDA calculation purposes.